SI1789036T1 - 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga - Google Patents
5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofagaInfo
- Publication number
- SI1789036T1 SI1789036T1 SI200531283T SI200531283T SI1789036T1 SI 1789036 T1 SI1789036 T1 SI 1789036T1 SI 200531283 T SI200531283 T SI 200531283T SI 200531283 T SI200531283 T SI 200531283T SI 1789036 T1 SI1789036 T1 SI 1789036T1
- Authority
- SI
- Slovenia
- Prior art keywords
- benzyloxyphenylthio
- imidazolidin
- fur
- dione
- inhibitors
- Prior art date
Links
- 108030001712 Macrophage elastases Proteins 0.000 title abstract 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- ZUOUZWHAINARGI-UHFFFAOYSA-N 5-[3-(4-phenylmethoxyphenyl)sulfanylfuran-2-yl]imidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1C1=C(SC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C=CO1 ZUOUZWHAINARGI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60273604P | 2004-08-19 | 2004-08-19 | |
| PCT/US2005/029259 WO2006023562A2 (en) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| EP05786673A EP1789036B1 (en) | 2004-08-19 | 2005-08-17 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1789036T1 true SI1789036T1 (sl) | 2011-09-30 |
Family
ID=35968136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200531283T SI1789036T1 (sl) | 2004-08-19 | 2005-08-17 | 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7179831B2 (enExample) |
| EP (1) | EP1789036B1 (enExample) |
| JP (1) | JP5042833B2 (enExample) |
| KR (1) | KR101197325B1 (enExample) |
| CN (1) | CN101014338B (enExample) |
| AT (1) | ATE508744T1 (enExample) |
| AU (1) | AU2005277432B2 (enExample) |
| BR (1) | BRPI0514470B8 (enExample) |
| CA (1) | CA2577430C (enExample) |
| DK (1) | DK1789036T3 (enExample) |
| ES (1) | ES2364068T3 (enExample) |
| MX (1) | MX2007001940A (enExample) |
| NZ (1) | NZ553258A (enExample) |
| RU (1) | RU2391339C2 (enExample) |
| SI (1) | SI1789036T1 (enExample) |
| WO (1) | WO2006023562A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090007281A1 (en) * | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| RU2719450C1 (ru) * | 2016-08-19 | 2020-04-17 | Форси Фармасьютикалз Ко., Лтд. | Фармацевтическая композиция и способы применения |
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| WO2018056373A1 (ja) * | 2016-09-23 | 2018-03-29 | 科研製薬株式会社 | （ｒ）‐５‐（３，４‐ジフルオロフェニル）‐５‐［（３‐メチル‐２‐オキソピリジン‐１（２ｈ）‐イル）メチル］イミダゾリジン‐２，４‐ジオンの製造方法およびその製造のための中間体 |
| LT3793995T (lt) * | 2018-05-15 | 2024-04-25 | Foresee Pharmaceuticals Usa, Inc. | Matrikso metaloproteinazės (mmp) inhibitoriai ir jų naudojimo būdai |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| RU2766551C1 (ru) * | 2021-07-19 | 2022-03-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1150975A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| RU2150469C1 (ru) * | 1999-06-01 | 2000-06-10 | Уфимский государственный нефтяной технический университет | Способ получения 2-(фурил-2)-1,3-имидазолидинов |
| AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| WO2002096426A1 (en) | 2001-05-25 | 2002-12-05 | Bristol-Myers Squibb Company | Hydantion derivatives as inhibitors of matrix metalloproteinases |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| AU2003282920A1 (en) * | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
-
2005
- 2005-08-17 EP EP05786673A patent/EP1789036B1/en not_active Expired - Lifetime
- 2005-08-17 JP JP2007527975A patent/JP5042833B2/ja not_active Expired - Fee Related
- 2005-08-17 US US11/205,954 patent/US7179831B2/en not_active Expired - Lifetime
- 2005-08-17 CA CA2577430A patent/CA2577430C/en not_active Expired - Fee Related
- 2005-08-17 AU AU2005277432A patent/AU2005277432B2/en not_active Ceased
- 2005-08-17 NZ NZ553258A patent/NZ553258A/en not_active IP Right Cessation
- 2005-08-17 SI SI200531283T patent/SI1789036T1/sl unknown
- 2005-08-17 DK DK05786673.3T patent/DK1789036T3/da active
- 2005-08-17 BR BRPI0514470A patent/BRPI0514470B8/pt not_active IP Right Cessation
- 2005-08-17 CN CN2005800285556A patent/CN101014338B/zh not_active Expired - Fee Related
- 2005-08-17 WO PCT/US2005/029259 patent/WO2006023562A2/en not_active Ceased
- 2005-08-17 ES ES05786673T patent/ES2364068T3/es not_active Expired - Lifetime
- 2005-08-17 KR KR1020077006294A patent/KR101197325B1/ko not_active Expired - Fee Related
- 2005-08-17 AT AT05786673T patent/ATE508744T1/de not_active IP Right Cessation
- 2005-08-17 RU RU2007105822/04A patent/RU2391339C2/ru not_active IP Right Cessation
- 2005-08-17 MX MX2007001940A patent/MX2007001940A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP5042833B2 (ja) | 2012-10-03 |
| CN101014338A (zh) | 2007-08-08 |
| EP1789036A2 (en) | 2007-05-30 |
| ES2364068T3 (es) | 2011-08-24 |
| US7179831B2 (en) | 2007-02-20 |
| KR20070045330A (ko) | 2007-05-02 |
| MX2007001940A (es) | 2007-07-24 |
| WO2006023562B1 (en) | 2006-06-22 |
| ATE508744T1 (de) | 2011-05-15 |
| DK1789036T3 (da) | 2011-06-27 |
| KR101197325B1 (ko) | 2012-11-05 |
| HK1107774A1 (en) | 2008-04-18 |
| CA2577430C (en) | 2010-12-07 |
| WO2006023562A3 (en) | 2006-04-20 |
| US20060041000A1 (en) | 2006-02-23 |
| BRPI0514470B8 (pt) | 2021-07-20 |
| RU2391339C2 (ru) | 2010-06-10 |
| NZ553258A (en) | 2011-02-25 |
| WO2006023562A2 (en) | 2006-03-02 |
| BRPI0514470A (pt) | 2008-06-10 |
| CA2577430A1 (en) | 2006-03-02 |
| AU2005277432B2 (en) | 2011-11-24 |
| EP1789036A4 (en) | 2008-08-27 |
| RU2007105822A (ru) | 2008-09-27 |
| CN101014338B (zh) | 2010-06-16 |
| BRPI0514470B1 (pt) | 2021-01-05 |
| EP1789036B1 (en) | 2011-05-11 |
| AU2005277432A1 (en) | 2006-03-02 |
| JP2008510701A (ja) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| ATE452631T1 (de) | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer | |
| NO20081636L (no) | FAP - inhibitorer | |
| TW200735865A (en) | Compositions of an anticonvulsant and methods of using the same for reversing weight gain | |
| NO20043645L (no) | Sykloalkylinhibitorer av kaliumkanal-funksjon | |
| LTPA2013018I1 (lt) | 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas | |
| FR2835186B1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
| DK2094107T3 (da) | Mykotoksin-reducerende sammensætning | |
| IL222698A0 (en) | Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors | |
| NO20053215D0 (no) | Pyrazolderivater med anvendelse som COX-1-inhibitorer. | |
| DK1776011T3 (da) | Fungicid sammensætning, indeholdende et syreamidderivat | |
| NO20082298L (no) | Kaliumkanalinhibitorer | |
| EP1559433A4 (en) | STABILIZED COMPOSITION | |
| TW200715969A (en) | Fungicidal active-compound combination | |
| ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
| SI1789036T1 (sl) | 5-(3-(4-benziloksifeniltio)-fur-2-il)-imidazolidin-2, 4-dion in analogi kot inhibitorji elastaze makrofaga | |
| AU2003234925A1 (en) | TGF-Alpha EXPRESSION INHIBITORS | |
| ATE382264T1 (de) | Trockenhefe-komposition | |
| MX2007002917A (es) | Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma. | |
| EP1767200A4 (en) | MEDIUM AGAINST SKIN AGING | |
| FI20020317A7 (fi) | Uudet tärkkelyspohjaiset liimat | |
| NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
| NO20071330L (no) | Enzyminhibitor i leukemi | |
| ATE493390T1 (de) | 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren | |
| WO2005113503A3 (en) | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |